Novo settles with med spa and weight loss clinic

Last week, Novo Nordisk reached confidential settlements in its trademark infringement lawsuits with a med spa and a weight loss clinic in Florida. As part of the settlement, permanent injunction orders require the two companies to stop using Novo trademarks and to disclose for 12 months that compounded semaglutide has not gone through the safety and efficacy standards required by the FDA for approved drugs.

These settlements are important reminders of what you can and cannot say about compounded medications in your marketing. So important, in fact, that we have a session at Owner Summit dedicated to the do’s and (definitely) do-not’s of compounding marketing claims. Led by PCCA Director of Member Engagement Erin Michael, it’s a session you can’t afford to miss. Register for Owner Summit here.